Bullish article touts Rocket Lab beyond Neutron, but financing and schedule risks remain

What happened

Seeking Alpha published a strong buy article on Rocket Lab citing record Q2 revenue of $234 million, 62% YoY growth, gross margin of 36.1%, backlog of $2.36 billion, and defense wins, arguing the investment case extends beyond Neutron. The article acknowledges Neutron's first flight may slip to 2027 but claims demand is secured and early capacity discipline supports margin maturation. However, the master report rates RKLB a WAIT with conviction 4.0, noting the stock already credits timely Neutron and manageable Iridium financing, while the 10-Q flags a narrowing launch window and a $3.6 billion bridge requiring permanent debt or equity. The article underemphasizes the dilution risk from the Iridium deal and the potential for further Neutron delays to reset the multiple. Fundamentally, the business is strong, but at $80 per share, the next 6-9 months hinge on binary proof points that remain unresolved.

Implication

The bullish article highlights real strengths, but it does not change the WAIT thesis that hinges on two binary events: Neutron first-stage qualification and permanent Iridium financing. Until those are resolved, the stock's valuation already prices in success, limiting near-term upside. A slip beyond Q4 2026 or worse-than-expected dilution could push shares back toward the bear case value of $64, while positive news could justify $96. Investors should monitor 90-day checkpoints: S-4 filing, FCC/foreign approvals, and qualification testing disclosures. Risk management suggests trimming above $95 and considering entry only near $65, with re-assessment in 3-6 months unless catalysts force a change.

Thesis delta

No material shift; the article reinforces the stand-alone business strength but does not resolve the two binary risks (Neutron timing and Iridium financing) that justify the WAIT rating. The bullish case assumes successful execution on these fronts, while the master report requires observable proof before upgrading. Confidence remains moderate, awaiting near-term catalysts.